The global hepatic encephalopathy market is witnessing strong growth with an increasing number of a

An increasing number of clinical trials for the development of new therapeutic products for liver diseases are propelling the growth of the global hepatic encephalopathy market. For instance, in December 2019, Kaleido Biosciences, Inc., a clinical-stage healthcare company announced positive results from a proof-of-concept clinical study, in which they used KB174, a novel microbiome metabolic therapy (MMT) in combination with a 15N-labeled tracer, a biomarker of microbiome am…

Leave a Reply

Your email address will not be published. Required fields are marked *